Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMSCRP1: Autologous CD34+ stem cells for retinitis pigmentosa
NCT04925687Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CD34+ cells in retinitis pigmentosa (RP), sponsored by University of California, Davis. Primary endpoints: Safety of intravitreal injection of autologous CD34+ cells at 6 months and Feasibility of intravitreal injection of autologous CD34+ cells. Started Jun 2021; status: completed.
02
Drugs
autologous CD34+ cells
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04925687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925687.